Search Results - "LEIGH, Bryan R"

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504 by GANDARA, David R, CHANSKY, Kari, CROWLEY, John, LIVINGSTON, Robert, ALBAIN, Kathy S, LEIGH, Bryan R, GASPAR, Laurie E, LARA, Primo N, BURRIS, Howard, GUMERLOCK, Paul, KUEBLER, J. Philip, BEARDEN, James D

“…To test the concept of taxane sequencing in combined-modality therapy, this phase II trial (S9504) evaluated consolidation docetaxel after concurrent…”
Get full text

Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma by CZUCZMAN, Myron S, THALL, Aron, SWEETENHAM, John, ALKUZWENY, Baha, FINUCANE, Deborah M, LEIGH, Bryan R, WITZIG, Thomas E, VASE, Julie M, YOUNES, Anas, EMMANOUILIDES, Christos, MILLER, Thomas P, MOORE, Joseph O, LEONARD, John P, GORDON, Leo I

“…This multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with…”
Get full text

A Phase I First-in-Human Study of TRC105 (Anti-Endoglin Antibody) in Patients with Advanced Cancer by ROSEN, Lee S, HURWITZ, Herbert I, THEUER, Charles P, LEIGH, Bryan R, GORDON, Michael S, WONG, Michael K, GOLDMAN, Jonathan, MENDELSON, David S, FIGG, William D, SPENCER, Shawn, ADAMS, Bonne J, ALVAREZ, Delia, SEON, Ben K

“…TRC105 is a chimeric IgG1 monoclonal antibody that binds CD105 (endoglin). This first-in-human, phase I, open-label study assessed safety, pharmacokinetics,…”
Get full text

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma by Wiseman, Gregory A, White, Christine A, Sparks, Richard B, Erwin, William D, Podoloff, Donald A, Lamonica, Dominick, Bartlett, Nancy L, Anthony Parker, J, Dunn, William L, Spies, Stewart M, Belanger, Richard, Witzig, Thomas E, Leigh, Bryan R

“…Radiation dosimetry studies were performed in patients with non-Hodgkin's lymphoma (NHL) treated with 90Y Zevalin™ ( 90yttrium ibritumomab tiuxetan, IDEC-Y2B8)…”
Get full text

Positron emission tomography imaging of CD105 expression with a 64Cu-labeled monoclonal antibody: NOTA is superior to DOTA by Zhang, Yin, Hong, Hao, Engle, Jonathan W, Bean, Jero, Yang, Yunan, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…Optimizing the in vivo stability of positron emission tomography (PET) tracers is of critical importance to cancer diagnosis. In the case of (64)Cu-labeled…”
Get full text

Phase II Study of Consolidation Paclitaxel After Concurrent Chemoradiation in Poor-Risk Stage III Non–Small-Cell Lung Cancer: SWOG S9712 by DAVIES, Angela M, CHANSKY, Kari, LAU, Derick H. M, LEIGH, Bryan R, GASPAR, Laurie E, WEISS, Geoffrey R, WOZNIAK, Antoinette J, CROWLEY, John J, GANDARA, David R

“…A previous Southwest Oncology Group (SWOG) study (S9429) demonstrated efficacy and tolerability of concurrent chemoradiotherapy in poor-risk stage III…”
Get full text

In vivo near-infrared fluorescence imaging of CD105 expression during tumor angiogenesis by Yang, Yunan, Zhang, Yin, Hong, Hao, Liu, Glenn, Leigh, Bryan R., Cai, Weibo

“…Purpose Angiogenesis is an indispensable process during tumor development. The currently accepted standard method for quantifying tumor angiogenesis is to…”
Get full text

Positron emission tomography imaging of CD105 expression during tumor angiogenesis by Hong, Hao, Yang, Yunan, Zhang, Yin, Engle, Jonathan W., Barnhart, Todd E., Nickles, Robert J., Leigh, Bryan R., Cai, Weibo

“…Purpose Overexpression of CD105 (endoglin) correlates with poor prognosis in many solid tumor types. Tumor microvessel density (MVD) assessed by CD105 staining…”
Get full text

A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors by Gordon, Michael S., Rosen, Lee S., Mendelson, David, Ramanathan, Ramesh K., Goldman, Jonathan, Liu, Lili, Xu, Yan, Gerson, Stanton L., Anthony, Stephen P., Figg, William D., Spencer, Shawn, Adams, Bonne J., Theuer, Charles P., Leigh, Bryan R., Weiss, Glen J.

“…Summary Introduction TRC102 potentiates the activity of cancer therapies that induce base excision repair (BER) including antimetabolite and alkylating agents…”
Get full text

ImmunoPET and near-infrared fluorescence imaging of CD105 expression using a monoclonal antibody dual-labeled with (89)Zr and IRDye 800CW by Zhang, Yin, Hong, Hao, Severin, Gregory W, Engle, Jonathan W, Yang, Yunan, Goel, Shreya, Nathanson, Alex J, Liu, Glenn, Nickles, Robert J, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…CD105 (endoglin) is an independent marker for poor prognosis in more than 10 solid tumor types. The goal of this study was to develop a CD105-specific agent…”
Get full text

Positron emission tomography imaging of CD105 expression with 89Zr-Df-TRC105 by Hong, Hao, Severin, Gregory W., Yang, Yunan, Engle, Jonathan W., Zhang, Yin, Barnhart, Todd E., Liu, Glenn, Leigh, Bryan R., Nickles, Robert J., Cai, Weibo

“…Purpose High tumor microvessel density correlates with a poor prognosis in multiple solid tumor types. The clinical gold standard for assessing microvessel…”
Get full text

Multimodality Imaging of Breast Cancer Experimental Lung Metastasis with Bioluminescence and a Monoclonal Antibody Dual-Labeled with 89Zr and IRDye 800CW by Hong, Hao, Zhang, Yin, Severin, Gregory W, Yang, Yunan, Engle, Jonathan W, Niu, Gang, Nickles, Robert J, Chen, Xiaoyuan, Leigh, Bryan R, Barnhart, Todd E, Cai, Weibo

“…Metastatic breast cancer is incurable. The goal of this study was to develop a positron emission tomography (PET)/near-infrared fluorescent (NIRF) probe for…”
Get full text

Choosing an optimal radioimmunotherapy dose for clinical response by DeNardo, Sally J., Williams, Lawrence E., Leigh, Bryan R., Wahl, Richard L.

“…Clinical trials have documented the single‐agent efficacy of radioimmunotherapy (RIT) in lymphoma, and several combination therapy studies are now in progress…”
Get full text

Additional radiation absorbed dose estimates for Zevalin radioimmunotherapy by Wiseman, Gregory A, Leigh, Bryan R, Dunn, William L, Stabin, Michael G, White, Christine A

“…Zevalin (ibritumomab tiuxetan) radioimmunotherapy is a novel treatment for non-Hodgkin's lymphoma (NHL). The Zevalin regimen includes 5 mCi (111)In-labeled…”
Get more information

Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia by Wiseman, Gregory A, Leigh, Bryan R, Erwin, William D, Sparks, Richard B, Podoloff, Donald A, Schilder, Russell J, Bartlett, Nancy L, Spies, Stewart M, Grillo-López, Antonio J, Witzig, Thomas E, White, Christine A

“…This was a 30-patient Phase II trial of reduced-dose (90)Y ibritumomab tiuxetan (Zevalin) RIT for patients with low-grade, follicular, or transformed B-cell…”
Get more information

Antiproliferative properties of toremifene on AIDS-related Kaposi's sarcoma cells by Hong, Angela, Leigh, Bryan R

“…Kaposi's sarcoma (KS) is the most common neoplastic apoptosis manifestation of acquired immunodeficiency syndrome. Toremifene is known to upregulate…”
Get more information

Acute toxicity of three-dimensional conformal radiotherapy in prostate cancer patients eligible for implant monotherapy by Chou, R H, Wilder, R B, Ji, M, Ryu, J K, Leigh, B R, Earle, J D, Doggett, R L, Kubo, H D, Roach, M, deVere White, R W

“…To assess the acute toxicity of three-dimensional conformal radiotherapy (3D-CRT) in prostate cancer patients eligible for implant monotherapy. Between…”
Get more information

Radioimmunotherapy of non-Hodgkin’s lymphoma: Clinical development of the Zevalin regimen by Theuer, Charles P., Leigh, Bryan R., Multani, Pratik S., Allen, Roberta S., Liang, Bertrand C.

“…Zevalin® (ibritumomab tiuxetan; IDEC Pharmaceuticals Corporation, San Diego, CA, USA) was approved by the United States Food and Drug Administration on…”
Get full text

Summary of the proceedings of the United States–Japan lung cancer clinical trials summit: San Francisco, CA, 20–22 November, 1998 by Leigh, Bryan R, Gandara, David R, Crowley, John J, Furuse, Kiyoyuki, Livingston, Robert B, Fukushima, Masanori, Coltman, Charles A

Get full text

Stem Cell Factor Enhances the Survival of Murine Intestinal Stem Cells after Photon Irradiation by Leigh, Bryan R., Khan, Waqqar, Hancock, Steven L., Knox, Susan J.

“…Recombinant rat stem cell factor (SCF) has been shown to decrease lethality in mice exposed to total-body irradiation (TBI) in the lower range of lethality…”
Get full text